Veeva Systems shares returned to their previous breakout range after the company issued its third-quarter outlook, with the stock still below its 21-day exponential moving average. Veeva maintained its target of $6 billion in revenue by 2030 and an operating margin of at least 35%, as investors weighed whether AI adoption in life sciences could support higher growth expectations. At 2:47 p.m. ET on Nov. 9, 2026, Veeva was at $307.35, up $3.62, or 1.19%. The quote was not real-time.
Veeva keeps its $6 billion revenue target
The Pleasanton, California-based software company provides biopharma businesses with tools to organize and store the large volumes of patient health data generated before, during and after clinical research, while meeting relevant regulatory standards. Veeva expects revenue to grow at a 13% compound annual rate to reach $6 billion by 2030, with an operating margin of at least 35%.
UBS analyst Karl Keirstead said the targets appear achievable, noting that Veeva's organic revenue growth is currently around 16% to 17%. The company has also said it does not need newer AI products, Vault AI and Falcon, to meet its medium-term goals. But Keirstead noted that Veeva has not changed those targets in two years despite growing interest in AI. That may reflect the life sciences industry's early stage of AI adoption, or the time still needed to refine and commercialize the technology.
The gap between AI's potential and its near-term contribution remains a focus for investors. AI applications in drug discovery and medical diagnostics could expand the market for research and clinical-trial software, but adoption and monetization may take time. Keirstead sees AI as more likely to add to Veeva's existing business than replace it. Veeva has said current AI models do not pose a competitive threat.
Life sciences AI opportunity tops $30 billion
At a virtual investor day on Nov. 5, Veeva said the biopharma and medical technology industries are growing by about 6% a year and put the addressable market for AI-related products in those sectors at more than $30 billion. The company described agentic AI as an important phase for life sciences, with the potential to help businesses discover new drugs. But drug-development applications remain at an early stage, and the timeline for producing practical results is uncertain.
Keirstead raised his price target on Veeva shares to $325 from $290, while keeping a Neutral rating. He said stronger investor interest in using AI models for drug development and diagnostics could lead to faster drug discovery, more clinical trials and greater use of Veeva's R&D software. When those possibilities might translate into revenue, however, remains difficult to determine.
Salesforce CRM migration window draws attention
Veeva also discussed its customer relationship management business. KeyBanc Capital Markets analyst Scott Schoenhaus said the company's comments on CRM were notably more confident and pointed to an opportunity to win back some Salesforce customers. Veeva previously partnered with Salesforce and now competes with it directly in the market.
Schoenhaus said a larger migration opportunity could emerge in 2027 and 2028, when some customers approach key transition deadlines and reconsider their long-term CRM platforms. He added that Veeva has a clearer view of its 20 largest customers, some of which have committed to Salesforce but have experienced difficulties with implementation. Schoenhaus rates Veeva Sector Weight.
Veeva forecast third-quarter adjusted earnings of $2.33 to $2.34 per share and revenue of $932 million to $935 million, saying it expected to meet or exceed its prior guidance. Keirstead called the growth solid but said he was disappointed that the company had not raised its longer-term targets.
Shares back in buy range and below the 21-day average
Veeva previously broke out of a flat-base pattern at a $296.24 buy point. After testing that level on Oct. 14 and 15, shares moved higher and then briefly left the buy range. They have since returned to it but remain below the 21-day exponential moving average. On Nov. 6, the stock fell more than 2% and slipped below that average.
Investors are watching whether shares can reclaim the 21-day average and break above a downtrend line that has been in place since Oct. 26. The Nov. 5 high of $314.23 is another technical level cited for attention. These chart levels do not change the fundamental questions around Veeva's revenue targets, quarterly outlook and progress in commercializing AI.
Veeva has a Composite Rating of 99 out of 99, placing it in the top 1% for stock performance, and a Relative Strength Rating of 93 out of 99, measuring its performance against the broader market over the past 12 months. Its industry group ranks fifth out of 197. Investors are also watching upcoming quarterly results and whether the company delivers on its long-term operating targets.